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Chemotherapy resistance is a key contributor to the dismal prognoses for lung cancer patients. While the majority of studies have
focused on sequence mutations and expression changes in protein-coding genes, recent reports have suggested that microRNA
(miRNA) expression changes also play an inﬂuential role in chemotherapy response. However, the role of genetic alterations at
miRNA loci in the context of chemotherapy response has yet to be investigated. In this study, we demonstrate the application of
an integrative, multidimensional approach in order to identify miRNAs that are associated with chemotherapeutic resistance and
sensitivity utilizing publicly available drug response, miRNA loci copy number, miRNA expression, and mRNA expression data
from independent resources. By instigating a logical stepwise strategy, we have identiﬁed speciﬁc miRNAs that are associated with
resistance to several chemotherapeutic agents and provide a proof of principle demonstration of how these various databases may
be exploited to derive relevant pharmacogenomic results.
1.Introduction
Lung cancer is the most common cause of cancer-related
deaths worldwide, with a ﬁve-year survival rate of less than
15%[1].Thehighincidenceoflate-stagediagnosisandalack
of eﬃcient therapeutic strategies remain key contributors
to the dismal survival statistics. Thus, to improve lung
cancer patient outcome, improvement in early detection and
a better understanding of the underlying tumor biology
that governs response to therapy are necessary. Response to
systemic therapy has been shown to be strongly associated
with a variety of clinical and molecular features. For exam-
ple, the chemotherapeutics Avastin and Permetrexed have
shown diﬀerential response or adverse eﬀects in diﬀerent
histological subtypes of lung cancer [2, 3]. Tyrosine kinase
inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have shown preferential eﬃcacy in Asian
femaleswhotypicallyharborsequencemutationsin EGFRas
well as those individuals who harbored EGFR ampliﬁcations,
EGFR mutations, and the absence of KRAS mutations [4–6].
Very recently, inhibitors to ALK rearrangement also showed
signiﬁcant response in patients who harbor this genetic
alteration [7].
In addition to molecular features that can predict
sensitivity, there are also examples of features that can
predict resistance. In ovarian cancer, resistance to therapy
was observed in those individuals who carried ampliﬁcations
o fg e n e ss u c ha sP - g l y c o p r o t e i na sw e l la ss p e c i ﬁ cr e g i o n s
in the genome such as 19q12 and 20q11.22-q13.12 [8, 9].
With respect to lung cancer, while there are individuals
who do respond to TKIs, a large proportion will develop
resistance to these therapies by acquiring an additional
EGFR mutation (T790M), ampliﬁcation of the c-MET
oncogene, or hypermethylation of the PTEN locus [10–12].
High levels of ERCC1 mRNA and protein, a key player
in nucleotide excision repair, have been associated with
resistance to platinum-based chemotherapy [13]. Similarly,
low levels of RRM1/2 mRNA and protein were associated
with favorable gemcitabine response in NSCLC patients
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Although alterations in protein-coding genes remain
a main focus to elucidate sensitivity or resistance to
chemotherapy, deregulation of microRNAs (miRNAs) has
recently been shown to play a role in chemotherapy response
[15–17]. miRNAs are small noncoding RNAs approximately
18–25 nucleotides in length that negatively regulate gene
expression posttranscriptionally [18, 19]. miRNA biogenesis
begins with a long, double-stranded RNA known as a pri-
miRNA, typically hundreds to thousands of nucleotides in
length, which is processed into sequentially shorter double-
stranded RNA sequences by the endonucleases Drosha and
Dicer that are of 70 and 22 nucleotides in size, respectively
[20, 21]. Dissociation of the duplex and incorporation of
the mature strand into the RNA-induced silencing complex
(RISC) guides RISC to the target mRNA, where the miRNA
exhibits its eﬀect [22]. miRNAs bind target transcripts
based on sequence similarity—typically in the 3 UTR of
the transcript and sometimes in the 5 UTR and the coding
region—resulting in inhibition of translation or transcript
degradation [18, 19, 23].
The relevance of miRNA deregulation to cancer biology
arises because increased expression of certain miRNAs
can result in downregulation of tumor suppressor genes,
while decreased expression of other miRNAs can lead to
increased expression of oncogenes [20, 21]. Often located at
chromosomal breakpoint regions, fragile sites, and minimal
regions of loss of heterozygosity or ampliﬁcation, miRNA
loci are highly susceptible to genomic alterations and sub-
sequently, deregulated expression [24–27]. Aberrant miRNA
expression is a common feature of both dysplasia and
cancer, and miRNA expression proﬁles have been associated
with prognosis, disease progression, survival, and outcome
prediction [28, 29]. Further, miRNA expression proﬁles have
been found to be superior to global mRNA expression
proﬁles for the accurate deﬁnition of cancer types [30, 31].
Lung cancer drug response has been associated with the
deregulation of several miRNAs. For example, sensitivity of
nonsmall cell lung cancer (NSCLC) to cisplatin treatment
was linked to upregulation of miR-181a, while resistance was
conferred by upregulation of miR-630 [32]. Sensitivity to
another chemotherapeutic agent, Geﬁtinib, was correlated
with loss of miR-128b [33]. Several studies have shown that
the overexpression of speciﬁc miRNAs, such as miR-134
and let-7a, can increase drug sensitivity, demonstrating the
therapeutic potential of miRNAs [34, 35].
In this study, we sought to determine the role of DNA
copy number alterations at miRNA loci in chemotherapy
response. As a proof of principle, making use of datasets gen-
erated by multiple institutions, encompassing we performed
an integrative and comparative DNA dosage and expression
alteration analysis of miRNA loci in highly sensitive and
resistant lung cancer cell lines for 18 diﬀerent chemother-
apeutics. Using a rigorous, stepwise analysis strategy, we
identiﬁed four miRNAs which were frequently gained and
overexpressed in lung cancer cell lines resistant to one or
two of ﬁve diﬀerent chemotherapeutic agents. Subsequent
gene expression and gene network analyses for each set
of mRNA targets of a given miRNA revealed functions
such as DNA replication and repair and cellular assembly
and maintenance that were overrepresented in all four
sets. These ﬁndings demonstrate the feasibility and the
value of integrative analysis of multidimensional publicly
accessible databases as a strategy for pharmacogenomics dis-
covery.
2.MaterialandMethods
2.1. Drug Response Proﬁles of Cancer Cell Lines. Drug
response IC50 data for 18 diﬀerent chemotherapeutics
across 350 cancer cell lines (See Supplementary Material
available online at doi: 10.1155/2011/474632 Supplemental
Table 1) was generated as part of the Wellcome Trust Sanger
Institute and Massachusetts General Hospital’s (MGH)
joint Genomics of Drug Sensitivity in Cancer Project. Data
was downloaded from the following website: (http://www
.sanger.ac.uk/genetics/CGP/translation/compound sens da-
ta.shtml). Brieﬂy, IC50 is the required concentration of a
particular drug to cause in vitro growth to be inhibited by
5 0 % ,a n dt h u s ,am e a s u r eo fd r u ge ﬀectiveness. A low IC50
indicates that a drug is very eﬀective at inhibiting growth
while a high IC50 indicates that a drug is less eﬀective and
thus requires a higher dosage to function. Of the 350 cancer
cell lines, 73 cell lines were of lung origin.
2.2. Generation of DNA Copy Number Proﬁles for Cancer Cell
Lines. Aﬀymetrix SNP 6.0 data for the cancer cell lines were
obtainedfromtheWellcomeTrustSangerInstituteCGPData
Archive (http://www.sanger.ac.uk/genetics/CGP/Archive/).
Of the 73 lung cancer cell lines with drug response data, 67
of them also had matching SNP array hybridization data
(Supplemental Table 2). SNP array data were normalized
using default parameters in Partek Genomics Suite (PGS,
Partek Inc, St. Louis, MI). Whole genome copy number
proﬁles were visualized using SIGMA2 software [36].
2.3. miRNA and mRNA Expression Data for Cancer Cell
Lines. The current annotation of autosomal miRNAs and
their genomic coordinates were obtained from the UCSC
Genome Browser (http://www.genome.ucsc.edu/) using the
NCBI36/hg18 mapping [37]. miRNA and mRNA expres-
sion proﬁles for lung cancer cell lines were downloaded
from the Broad Institute (http://www.broadinstitute.org/cgi-
bin/cancer/datasets.cgi)underthe“SangerCellLineProject.”
Aﬀymetrix HG-U133A mRNA expression data were RMA-
normalized using the “aﬀy” package in Bioconductor in R
[38–40]. Mapping of probes to genes was performed using
the Aﬀymetrix NetAﬀx annotation ﬁle (version NA31). Of
the 73 lung cancer cell lines with drug response data, 64 had
matching miRNA expression while 68 had matching mRNA
expression data (Supplemental Table 2).
2.4. Determination of Predicted miRNA Targets. TargetSpy
(version 1.0) and TargetScan (version 5.1) miRNA target
prediction software were used to identify mRNA targets
for further analyses [41–44]. For TargetSpy, the “no seed
requirement, high sensitivity” set of targets were used, while
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were used. For the miRNAs that were further assessed for
target analysis, only miRNA-mRNA target pairs that were
present in both databases were assessed for gene expression
diﬀerences.
2.5. Statistical Analysis. For DNA alteration analysis, copy
number proﬁles of the cancer cell lines were determined
against a pooled reference comprised of 72 cytogenetically
normal individuals in the HapMap collection. SNP 6.0
data for the HapMap individuals were obtained through
Aﬀymetrix. Subsequently, to determine copy number gains
and losses, copy number proﬁles were subjected to segmen-
tation analysis using the “Genomic Segmentation” algorithm
in PGS with the following parameters: minimum genomic
markers = 20, P-value threshold for adjacent regions having
signiﬁcantly diﬀerent means = 1 × 10
−6,a n dP-value
threshold for deviation from normal (diploid) copy number
= 1 × 10
−6. In addition to meeting P-value thresholds, a
region was deemed gained if the cell line had >2.3 copies
while a region was deemed lost if the cell line has <1.7 copies.
For each cell line, the copy number status for individual
miRNA loci were determined by mapping the genomic
coordinates of the miRNA loci to the identiﬁed regions of
alteration.
T od e t e r m i n em i R N Al o c ii nd i ﬀerentially altered regions
of copy number between highly resistant and sensitive cell
lines,foreachchemotherapeutic,celllineswererankedbased
on their IC50 value. The frequency of copy number gain,
loss, and retention were compared between the top 1/3 and
bottom 1/3 of cancer cell lines using a 3 by 2 Fisher’s exact
test. A miRNA was deemed signiﬁcant if the P value from the
Fisher’s exact test was ≤.05.
For miRNA and mRNA expression analysis, similar to
the diﬀerential copy number analysis, cell lines were ranked
based on IC50 for each drug. Subsequently, for each miRNA,
the expression in the top and bottom tertiles of cell lines was
compared using a nonparametric Mann Whitney U test. A
miRNA was deemed signiﬁcant if the P value from the Mann
Whitney U test was ≤.05.
Upon identifying which lung cancer cell lines (LCCLs)
contained matching DNA copy number and drug response
proﬁles, for each chemotherapeutic, we compared the pat-
terns of copy number alteration between the most sensitive
and resistant LCCLs for 636 miRNA loci. Of the resulting
diﬀerentially altered miRNA identiﬁed using the above
statistical criteria, we ﬁltered out those miRNAs which were
both preferentially gained and lost in either highly resistant
or highly sensitive LCCLs. We deﬁned these variably altered
miRNAs as those whose diﬀerential alteration frequency
(DAF)ofgain,frequencyofgaininhighlyresistantminusthe
frequency of gain in highly sensitive, was within 10% of the
DAF of loss, which is the frequency of loss in highly resistant
minus the frequency of loss in highly sensitive. In parallel,
upon identifying LCCLs with both miRNA expression and
drug response proﬁles, we compared the miRNA expression
proﬁles between the most sensitive and resistant LCCLs
for 254 miRNAs using the above-mentioned statistical
methods. Although 418 unique miRNAs are represented
on the microarray platform, we restricted this analysis to
the 254 miRNAs that were expressed in at least 4 LCCLs.
Subsequently,foreachdrug,weidentiﬁedthemiRNAswhich
were both signiﬁcantly diﬀerent at the DNA copy number
and expression levels that matched in the same direction
that is, if a miRNA had higher copy number in the highly
resistant LCCLs as compared to the highly sensitive LCCLs,
then the expression would also have to be higher, and
vice versa. Next, for each signiﬁcant miRNA, bioinformatic
analysis was performed to identify target mRNAs, and
mRNA expression proﬁles for these genes were compared
in a similar manner to that performed in the diﬀerential
DNA copy number and miRNA expression analyses (using
TargetSpy and TargetScan; see above). Restricting to those
targets whose mRNA expression proﬁles negatively correlate
withmiRNAexpressionproﬁles,weperformedgenenetwork
and function analysis using Ingenuity Pathway Analysis to
identify signiﬁcantly overrepresented functions that were
common to all sets of diﬀerentially expressed miRNA
targets. A ﬂow chart illustrating this strategy is shown in
Figure 1.
2.6. Gene Network and Pathway Analysis. For each miRNA,
the set of diﬀerentially expressed target genes were analyzed
using Ingenuity Pathway Analysis (Ingenuity Systems, Red-
wood City, CA) to determine statistically overrepresented
networks and pathways. Brieﬂy, a right tailed Fisher’s exact
test was employed to calculate a P-value for the probability
that enrichment of functions within the gene list of interest
and the entire list of genes in the human genome is due
to chance alone. Only the Molecular and Cellular Functions
within the Biological Functions analysis were assessed.
3. Results
3.1. Copy Number Alterations of miRNA Loci Correlate with
Drug Response in Lung Cancer Cell Lines. Sixty seven lung
cancer cell lines with available IC50 data were used to analyze
miRNA copy number alterations. For each drug, cell lines
were sorted based on IC50 values and the frequencies of
DNA copy number gain, loss, and retention were compared
between the highest (most resistant, n = 22) and the lowest
(most sensitive, n = 22) tertile of cell lines. Of the 636
miRNAs assessed, 307 miRNAs (48.3%) were signiﬁcantly
diﬀerent between high and low IC50 for at least one drug,
and 20 miRNAs (3.1%) were diﬀerent for at least four drugs
(P ≤ .05 Fisher’s exact test, Table 1, Supplemental Table 3).
Inaddition,amongthe307miRNAs,58.4%wereeithermore
frequently gained in high IC50 or more frequently lost in
low IC50 while 23.6% were either more frequently lost in
high IC50 or more frequently gained in Iow IC50 lung cancer
cell lines. The remaining 41 miRNAs (17.9%), although
signiﬁcantly diﬀerent, had less than a 10% DAF diﬀerence
between resistant and sensitive lines and were, therefore,
deemed variably altered (see methods) and subsequently
removed. This brought the total number of miRNAs with
signiﬁcant diﬀerences in copy number to 266 (Figure 2).
In terms of the drug with the most striking pattern of4 Journal of Biomedicine and Biotechnology
Perform Ingenuity Pathway Analysis
for each set of identiﬁed mRNAs
Identify diﬀerentially expressed mRNAs
whose expression is negatively correlated
with each miRNA of interest
Assess mRNA targets for diﬀerential expression between
the most sensitive and resistant tertiles of 68LCCLs for
each drug and miRNA previously identiﬁed using mRNA
expression proﬁles obtained from the Broad Institute
Identify mRNA targets that are common
between TargetScan and TargetSpy
Determine predicted
TargetScan mRNA
targets
Determine predicted
TargetSpy mRNA
targets
Identify miRNAs gained or lost with
appropriate diﬀerential expression
for each drug
Integrate diﬀerential miRNA gene
dosage and expression analyses for
miRNAs represented on miRNA
expression platform
Filter for miRNAs with unambiguous
CNA between the most sensitive and
resistant tertiles
Identify diﬀerentially expressed
miRNAs between the most
sensitive and resistant tertiles for
each drug in 64LCCLs
Identify diﬀerentially gained and lost
miRNA loci between the most
sensitive and resistant tertiles for
each drug in 67LCCLs
Analyze miRNAs which are expressed
in at least 4 LCCLs of 64 LCCLs (254
miRNAs)
Generate copy number proﬁles for
all 636 currently annotated miRNAs
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Trust Sanger Institute CGP Data
Archive (n = 128LCCLs)
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analyzed by the Wellcome Trust
Sanger Genomics of Drug
Sensitivity in Cancer Project
(n = 73LCCLs)
Obtain miRNA expression proﬁles
for 418 miRNAs from the Broad
Institute (n = 117LCCLs)
Figure 1: The search for drug response-related miRNAs began with data acquisition from several independent databases. Drug response
data for lung cancer cell lines (LCCLs) was integrated independently with copy number and expression data, and unique ﬁltering criteria
were applied. The integration of all three dimensions applied further ﬁltration criteria, and the remaining miRNAs underwent predicted
target analysis. The resulting mRNA target expression was anticorrelated with miRNA expression, and cellular functions of the ﬁnal mRNA
target list were derived by Ingenuity Pathway Analysis.Journal of Biomedicine and Biotechnology 5
Our analysis reveals 4miRNAs miR-10b,
-193b, -328, and -628 with signiﬁcant
diﬀerential copy number and expression
alterations in the same drug
138 of the 266miRNAs have
expression proﬁles, but only 66
have expression in 4 or more lines
Of the 254miRNAs, 134
show signiﬁcantly
diﬀerential expression
Align
After removing ambiguously
directional miRNAs, 266 remain
307miRNAs show signiﬁcantly
diﬀerent alterations between
resistant and sensitive cell lines
Copy number proﬁles are
available for 636miRNAs
Copy number proﬁles Expression proﬁles
Filtering for miRNAs with expression in
at least 4 cell lines leaves 292probes
representing 254miRNAs
498 probes, corresponding to 418
unique miRNAs, are represented on the
miRNA expression array platform
Figure 2: Flowchart summarizing the process for the identiﬁcation of the four miRNAs which correlated signiﬁcantly with drug response.
diﬀerential alteration between high and low IC50 cell lines,
TAE684, a small molecule ALK fusion kinase inhibitor,
had 66 miRNAs that were signiﬁcantly diﬀerent between
the most resistant and most sensitive cell lines (Figure 3).
Conversely, miR-662 was the most frequently diﬀerentially-
altered miRNA across all of the drugs, appearing signiﬁcant
i n6o f1 8d r u g s .
3.2. miRNA Expression Levels Correlate with Drug Response
in Lung Cancer Cell Lines. miRNA expression was assessed
in 64 lung cancer cell lines using a similar method to that
applied for identifying copy number alteration diﬀerences,
comparison of the highest and lowest tertile of cell lines (n =
21) based on IC50 values for each drug. miRNA expression
proﬁles were available for 498 probes measuring 418 unique
miRNAs. However, a number of miRNAs have little to
no expression. To account for these cases, miRNAs with
expression in less than four cell lines were removed, leaving
292 probes which corresponded to 254 unique miRNAs
(Figure 2). One hundred thirty four miRNAs (represented
by 146 probes) of the 254 (52.8%) miRNAs with available
expression data were signiﬁcant in at least one drug (P ≤
.05, Mann Whitney U test) (Supplemental Table 4), with
18 miRNAs signiﬁcant in at least four drugs (Table 2). Of
the 134 diﬀerentially expressed miRNAs, 40% had higher
expression in high IC50, while 60% had higher expression
in low IC50 lung cancer cell lines. HKI-272 had the most
miRNAs [30] that were signiﬁcantly diﬀerent at the expres-
sion level (Figure 4), and miR-625 was the most frequently
diﬀerentially expressed miRNA, appearing signiﬁcant in 7 of
18 drugs.
Table 1: List of miRNA with most frequent diﬀerential copy
number alterations.
miRNA Signiﬁcant drugs
hsa-mir-662 6 (AZ, Erl, Gel, G¨ o, HKI, MK)
hsa-mir-124-2 5 (Erl, HKI, Ra, Sor, Sun)
hsa-mir-1285-2 5 (MG, PF, PH, Ra, Sun)
hsa-mir-548h-2 5 (Gel, HKI, MK, PD, Sor)
hsa-mir-1208 4 (Cy, Erl, HKI, Sun)
hsa-mir-1225 4 (AZ, G¨ o, MK, Sor)
hsa-mir-1228 4 (Gel, MK, PF, TAE)
hsa-mir-1299 4 (AZD, Erl, MK, PH)
hsa-mir-147 4 (Erl, HKI, MK, TAE)
hsa-mir-181a-2 4 (Erl, HKI, MK, TAE)
hsa-mir-181b-2 4 (Erl, HKI, MK, TAE)
hsa-mir-1827 4 (AZ, Gel, Pac, PF)
hsa-mir-1972 4 (AZ, G¨ o, MK, Sor)
hsa-mir-492 4 (Gel, Im, Pac, PF)
hsa-mir-548c 4 (Gel, MK, PF, TAE)
hsa-mir-548d-1 4 (Cy, G¨ o, HKI, Sun)
hsa-mir-548f-2 4 (G¨ o, MG, PF, TAE)
hsa-mir-600 4 (Erl, HKI, MK, TAE)
hsa-mir-601 4 (Erl, HKI, MK, TAE)
hsa-mir-940 4 (AZ, G¨ o, MK, Sor)
3.3. Integrative Analysis of miRNA Gene Dosage and Expres-
sionLevelsinLungCancerCellLines. TodetermineifmiRNA
dosage modulates expression, we compared the 266 miRNAs6 Journal of Biomedicine and Biotechnology
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Figure 3: Comparison of the frequency of alteration of 636 miRNA loci between highly sensitive and highly resistant lung cancer cell lines
(LCCLs)toagentTAE684.HighlysensitiveLCCLswererepresentedbythelowesttertileofIC50 whilethehighlyresistantwererepresentedby
the highest tertile of IC50. miRNA genomic position information was obtained from the UCSC Genome Browser database [37], and miRNAs
on chromosomes X and Y were excluded. Copy number alterations frequencies were plotted using SIGMA2 software [36]. Vertical lines
denote the frequency of alteration, where 1 or −1 signiﬁes the alteration that occurs in 100% of samples. Horizontal bars depict miRNAs,
with the frequency of copy gains and losses of each miRNA displayed to the right and left of 0, respectively. miRNAs disrupted in resistant
lines are displayed in red, those occurring in sensitive lines are displayed in green, and regions of overlapping frequencies are shown in black.
diﬀerentially altered at the copy number level and the
134 miRNAs diﬀerentially expressed in at least one of the
drugs analyzed. Considering only those miRNAs that were
signiﬁcant at both the copy number and miRNA expression
level for the same drug, the intersection of these two lists
yielded ﬁve miRNAs, miR-10b, -191, -193b, -328,a n d-628
(Figure 2). Of these ﬁve, only expression of four miRNAs,
mir-10b, -193b, -328,a n d-628 matched the direction of
their respective copy number alterations. For example, miR-
628 is more frequently gained in high IC50 lines compared
to low IC50 lines treated with agent PF-2341066 and also
shows higher expression in high IC50 lines compared to low
IC50 lines (Table 3), whereas miR-191 is frequently gained in
low IC50 lines when treated with TAE684, but shows higher
expression in high IC50 lines.
3.4. Gene Expression Analysis of mRNA Targets of miR-10b,
miR-193b, miR-328, and miR-628. The target prediction
software TargetScan and TargetSpy were used to identify
putative mRNA targets of miRNAs found to be signiﬁcantly
diﬀerent at the copy number and miRNA expression levels
between high-IC50 and low-IC50 cell lines. For the four miR-
NAs (miR-10b, miR-328, miR-193b,a n dmiR-628) identiﬁed
by integrative analyses, only miRNA-mRNA targets present
in both databases were used for further analysis.
miR-10b was identiﬁed as having a signiﬁcant association
with response to the proteosome inhibitor MG-132. In total,
target prediction analysis found 636 genes that were deemed
as putative targets of miR-10b (Supplemental Table 5).
Comparison of the gene expression proﬁles between lung
cancer cell lines with high and low IC50 for MG-132
revealed 48 of these target genes to be diﬀerentially expressed
(P ≤ .05, Mann Whitney U test), with 32 of them
showing the expected direction of diﬀerential expression
(i.e., anticorrelated mRNA expression to miRNA expression)
(Table 4).
Interestingly, miR-193b alteration was signiﬁcantly asso-
ciated with response to two therapeutics: AZ628 and
MK0457 (RAF and aurora kinase inhibitors, resp.). When
a similar analysis to hsa-miR-10b was performed for miR-
193b, 518 genes were identiﬁed as putative targets of miR-
193b (Supplemental Table 5). For the analysis of gene
expressionbetweenhighlysensitiveandresistantAZ628cells,
28 of these targets were diﬀerentially expressed, with ten of
these genes matching the expected direction of diﬀerential
expression. For MK-0457, 67 of these target genes were
diﬀerentially expressed with over half (37) matching the
expected direction (Table 4).
Alteration of miR-328 was signiﬁcantly associated with
the response to Hsp90 inhibitor Geldanamycin in lungJournal of Biomedicine and Biotechnology 7
Table 2: Most frequently diﬀerent miRNAs at the expression level.
miRNA Signiﬁcant drugs
hsa-mir-625 7 (Erl, G¨ o, HKI, MG, Pa, PHA, Ra)
hsa-mir-130a 6 (Erl, G¨ o, HKI, MG, Pa, Sun)
hsa-mir-148a 6 (AZ, Erl, Gel, G¨ o, HKI, Pa)
hsa-mir-215 5 (Gel, G¨ o, MG, MK, Pa)
hsa-mir-518b 5 (Cy, PF, PHA, Ra, Sun)
hsa-mir-100 5 (Erl, G¨ o, HKI, Sun, TAE)
hsa-mir-192 5 (Gel, G¨ o, MG, MK, Pa)
hsa-mir-375 5 (Erl, Gel, G¨ o, HKI, Pa)
h s a - m i r - 5 0 3 5( C y ,E r l ,M K ,P H A ,R a )
hsa-mir-193b 4 (AZ, MK, PHA, Ra)
h s a - m i r - 5 2 1 4( C y ,E r l ,I m ,P H A )
hsa-mir-95 4 (Cy, Erl, MG, Sun)
hsa-mir-194 4 (Gel, G¨ o, MG, Pa)
hsa-mir-205 4 (Erl, Gel, G¨ o, HKI)
hsa-mir-222 4 (AZ, Erl, Gel, HKI)
hsa-mir-27a 4 (AZD, Erl, Gel, G¨ o)
hsa-mir-377 4 (MG, Pa, Sor, Sun)
hsa-mir-382 4 (AZD, MG, Pa, Sun)
cancer cell lines. Of the 437 genes targeted by miR-328,
49 of these genes were signiﬁcantly diﬀerentially expressed
between highly resistant and sensitive cell lines, with 31 of
the genes matching the expected direction (Supplemental
Tables 5 and 4). Finally, for miR-628, whose alteration was
signiﬁcantly associated with the MET inhibitor PF-2341066
response, 392 targets genes were identiﬁed with 49 of
them being diﬀerentially expressed and 22 of those in the
appropriate direction (Supplemental Tables 5 and 4).
4. Discussion
Chemotherapy response can be inﬂuenced by a number of
clinicopathological and molecular factors. At the molecular
level,whilealargefocusrevolvesaroundtheroleofactivating
and inactivating sequence mutations as well as copy number
ampliﬁcations and deletions in protein coding genes, there
has been an increasing emphasis on examining the role of
miRNAs and response to chemotherapy. Recent studies have
focused on diﬀerentially expressed miRNAs in conjunction
toresistanceandsensitivitytoavarietyofchemotherapeutics
[32–35, 45, 46]. However, the inﬂuence of copy number
alterations at miRNA loci (or gene dosage) in the context of
drug response has not been thoroughly investigated. To this
end, we have performed an integrative analysis of genome-
wide miRNA copy number, miRNA expression, mRNA
expression, and drug sensitivity data from 18 diﬀerent
chemotherapeutics on a panel of lung cancer cell lines to
identify miRNAs that are signiﬁcantly diﬀerent at the copy
numberandexpressionlevelsbetweenthemostsensitiveand
resistant cell lines for a given drug.
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Figure 4: Heatmap visualization of the miRNA expression of
the 254 miRNAs (represented by 292 unique probes) that passed
expression ﬁltering criteria for the 21 most sensitive (yellow bar,
low IC50) and 21 most resistant (blue bar, high IC50)t od r u gH K I -
272.Intotal,30miRNAswerefoundtobesigniﬁcantlydiﬀerentially
expressed between the most sensitive and resistant lung cancer cell
lines (LCCLs, orange bar). For this visualization, since a value of 4
represented no expression, all expression values were subtracted by
4 such that baseline expression would be shown as 0 (black).
Upon comparison of the 636 annotated miRNAs
throughout the human genome, it was found that 266
of them revealed signiﬁcant diﬀerences in copy number
alteration pattern between sensitive and resistant cancer cell
lines for at least one drug (Supplemental Table 3). Moreover,
of the 266 miRNAs, there were more miRNAs with increased
copy number for the highly resistant versus the highly
sensitive lung cancer cell lines than vice versa. The miRNA
that was found to have a diﬀerential pattern of copy number
alteration between sensitive and resistant cancer cell lines for
the most drugs was miR-662, and, conversely, the drug with
most signiﬁcantly diﬀerent miRNAs was TAE684. miR-662 is8 Journal of Biomedicine and Biotechnology
Table 3: List of miRNAs with signiﬁcant copy number and expression alterations in the same drug.
miRNA Copy number alteration Expression alteration Drug in which signiﬁcant
hsa-mir-10b Gained, High IC50 Overexpressed, High IC50 MG-132
hsa -mir-193b Gained, High IC50 Overexpressed, High IC50 AZ628, MK-0457
hsa-mir-328 Gained, High IC50 Overexpressed, High IC50 Geldanamycin
hsa-mire-628 Gained, High IC50 Overexpressed, High IC50 PF-2341066
Table 4: Diﬀerentially expressed mRNA targets for the four identiﬁed miRNAs.
miRNA 10b 328 193b 193b 628
Drug MG-132 (26S
Proteasome inhibitor)
Geldanamycin
(HSP90 inhibitor)
AZ628 (RAF
inhibitor)
MK-0457 (Aurora
kinase inhibitor)
PF-2341066 (MET,
ALK inhibitor)
Targets
SMARCC1 SLC16A1 PHF15 EIF2S1 DCTD
MKRN2 ANGEL1 RPP30 ARIH2 NUP188
CMTM6 UBR5 RRP1B TMEM231 ELAC1
CSDE1 SEMA3C EIF4B GABBR1 DACT1
MAP4 MEIS2 WDR48 IKZF1 CYP7B1
MYO10 TRIM32 PTPN21 FKTN RPA4
NKTR GM2A CLEC2D GPATCH8 GAR1
RYBP EIF2S1 MRPS16 EZH1 UCKL1
ZNF532 RAC2 NUDT15 OLFML2A IL7
SENP5 OLFML2A NECAP2 PSME3 ABCE1
CBL HIP1 AGTPBP1 CASP3
WHSC1 PRKD3 NMT2 WBP4
FOXJ2 VDR ADARB1 KLF9
APOLD1 YME1L1 GREB1 ACTN2
PEA15 TP63 SMC5 GPM6A
RAD1 TFAP2C CCDC28A LSM12
CDC6 CHP2 RNMT PRKCA
UBE2K STK24 C15orf29 ADAT1
BNIP2 GPR126 RRP1B PBRM1
PARD6B SERTAD2 AGPAT4 SP2
FGD6 DSC2 UBA52 TRAIP
MMP14 PTGIS GOSR1 MAGOHB
OLFML2A RAB22A PRKD3
GNL3L FBXW2 SYF2
CTDSPL HS2ST1 SSX2IP
MME RPP30 ANKH
PPFIBP1 SLC16A3 ZBTB39
M6PR MAN1A2 KBTBD11
KPNA6 TGIF2 SEC16A
RMI1 CLEC2D PHC3
RBM15B ZNF510
SS18L2 RTF1
CYLD
WDR48
BTRC
CCNT2
RAB36Journal of Biomedicine and Biotechnology 9
locatedonchromosomalregion16p13.3andwasfoundtobe
morefrequentlygainedincelllineshighlyresistanttoAZ628,
Erlotinib, Geldanamycin, G¨ o-6976, HKI-272 (Neratinib),
and MK-0457. All of these drugs, except for Geldanamycin,
whichisanantibodythattargetsHSP90,arekinaseinhibitors
[47]. While not much is known of miR-662,i tw a sr e c e n t l y
shown that it is transiently upregulated in response to high
doses of X-ray radiation in human ﬁbroblasts [48]. It should
also be noted that miR-124-2, miR-1285-2, and miR-548h-2
were signiﬁcantly altered for ﬁve drugs (Table 1). Similar to
miR-662, little is known of miR-548h-2.H o w e v e r ,miR-124
has been shown to play a tumor suppressive role in cervical
cancer, hepatocellular carcinoma, and glioblastoma, while
miR-1285 inhibits p53 and p21 expression by targeting the
3 UTR of p53 transcript [49–52].
To identify diﬀerentially expressed miRNAs in our
dataset, we employed the same approach used to identify dif-
ferential copy number alterations by assessing the expression
of 254 miRNAs in 64 lung cancer cell lines. We identiﬁed
134 unique miRNAs signiﬁcantly diﬀerent at the expression
levelbetweenresistantandsensitivelinesinatleastonedrug.
Of which, 40% overexpressed in highly resistant and 60%
overexpressed in highly sensitive lung cancer cell lines. Of
these 134 miRNAs, miR-625, about which little is known
regarding function, was the most frequently diﬀerentially
expressed. It was signiﬁcantly diﬀerentially expressed in the
analyses of agents Paclitaxel, HKI-272, G¨ o-6976, Erlotinib,
Rapamycin, PHA665752, and MG-132. In terms of the
drug comparisons with the highest number of diﬀerentially
expressed miRNAs, the comparison between LCCLs highly
sensitive and resistant to HKI-272, an irreversible tyrosine
kinase inhibitor of HER2, revealed 30 diﬀerentially expressed
miRNAs.
Previous studies of miRNA deregulation with respect to
response of some of the drugs used in our analyses have
identiﬁed a number of miRNAs whose expression correlates
with drug sensitivity. For example, underexpression of miR-
34a and overexpression of miR-125b, 2-21,- 222 ,a n d- 923
confer Paclitaxel resistance in prostate cancer [53]a n d
breast cancer [54], respectively, while for hepatocellular
carcinomas expression of let-7c [55], miR-122 [56]a n dmiR-
193b [57] confer sensitivity to Sorafenib. Notably, Sorafenib
is a multikinase inhibitor with highest potency for RAF;
this is consistent with our ﬁndings that link mir-193b with
resistance to the RAF inhibitor AZ628. In addition, underex-
pression of miR-130a and -126 was correlated with resistance
to Paclitaxel [58] and Imatinib [59], respectively. From our
analyses, we observed miR-130 and -126 to be overexpressed
in lung cancer cell lines sensitive to Paclitaxel and Imatinib.
Cancer genomes are characterized by widespread genetic
aberrations including high-level ampliﬁcations, deletions,
DNA methylation, mutations, and chromosomal rearrange-
ments. Within the hundreds of alterations in a cancers
genome, only a small subset of these alterations drive
tumor initiation and progression and DNA alterations with
corresponding expression alterations are more likely to
contribute to tumorigenesis [60, 61]. To identify miRNAs
likely implicated in drug resistance, we integrated the 266
miRNAs that were signiﬁcantly diﬀerent at the copy number
level and the 134 miRNAs that were signiﬁcantly diﬀerent
at the expression level and subsequently ﬁltered for those
miRNAs that were diﬀerentially expressed and altered in
the same drug. Our analysis identiﬁed four miRNAs, miR-
10b,- 193b,- 328,a n d- 628, that met these criteria. While
the overlap of signiﬁcant miRNAs in the same drug is
minimal, stringent selection criteria such as P ≤ .05 for
both copy number and expression alterations, and limited
miRNA expression data, likely contributed to the small
number of overlapping miRNAs. Importantly, many of the
miRNAs most frequently diﬀerentially altered at the copy
number level (128 of 266, 48.1%) were not represented on
the microarray platform. Moreover, when we factored in our
expression criteria of expression in at least four cell lines, the
numberofmiRNAswithexpressionproﬁlesandsigniﬁcantly
diﬀerent copy number alterations was reduced to 66. The
copy number proﬁles of these miRNAs suggest they may
play an important role in drug resistance, dictating the
importance and need to assess these uninvestigated miRNAs
at the expression level.
The observation that miR-10b is diﬀerentially gained
and overexpressed in resistant cell lines treated with MG-
132 is consistent with previous ﬁndings (Figures 5(a) and
5(b)). miR-10b is an oncomir whose overexpression has been
identiﬁed in a variety of cancers [62–67]. Speciﬁcally, over-
expression of miR-10b has been demonstrated to promote
the development of metastatic disease in breast cancer and
correlate with clinical breast cancer progression, poor overall
survival in gastric cancer, and higher grades of malignant
glioma. It was also found to be an eﬀective therapeutic
target by using antagomirs to reduce expression of HOXD10,
subsequently suppressing breast cancer metastasis [62, 64,
66,68].BioinformaticandgeneexpressionanalysisofmRNA
targets of miR-10b revealed 32 of 636 target genes that were
underexpressed in highly resistant cell lines, which have
high expression of miR-10b. Amongst the identiﬁed genes
was RAD1 (Figure 5(c)). RAD1 is part of a complex of
proteins known as the 9-1-1 complex, which functions as
a heterotrimeric cell cycle checkpoint [69]. The complex,
which functions in DNA repair, is recruited to the site of
DNA damage or incomplete replication where it recruits
DNA polymerases and DNA repair enzymes. RAD1 has been
shown to be important in preventing tumor development
in response to DNA damage in mice, whereas deletion of
RAD1 greatly increased the susceptibility for skin tumor
development [70]. In addition, RAD1 is an important com-
ponent of nucleotide excision repair (NER) which can have
drastic eﬀects on chemotherapy drug response. In drugs that
instill double stranded DNA breaks, such as the platinum
based treatment Cisplatin, upregulation of NER increases
drug resistance while in certain non-DNA damage based
chemotherapies, downregulation of NER has been shown
to increase resistance [71, 72]. In NSCLC patients that have
low expression of ERCC1, a gene also involved with NER,
havedecreasedsurvivalwhencomparedtopatientswithhigh
ERCC1 expression [73], and in both murine and human
cells, low XPC expression, another gene involved in NER,
correlated with resistance to the Doxorubicin derivative,
Nemorubicin [72]. Intriguingly, one of the overrepresented10 Journal of Biomedicine and Biotechnology
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Figure 5: Example of a miRNA showing diﬀerentially copy number alteration, diﬀerential miRNA expression, and diﬀerential target gene
expression. (a) Copy number alteration comparison between cell lines which are highly resistant and sensitive to agent MG-132 revealed that
the hsa-miR-10b locus, on chromosomal region 2q31.1, is more frequently gained in the highly resistant cell lines (P<. 05, Fisher’s exact
test). (b) miRNA expression analysis of miR-10b shows that expression is signiﬁcantly higher in highly resistant cell lines as compared to
sensitive cell lines to MG-132 (P = .03, Mann Whitney U test). (c) mRNA expression analysis of RAD1, a gene identiﬁed by bioinformatics
predictionanalysisasaputativetargetofmiR-10b,showsanticorrelativeexpressiontomiR-10bexpression.Speciﬁcally,decreasedexpression
of RAD1 in highly resistant cell lines to MG-132 relative to highly sensitive lines is observed.
functions identiﬁed by Ingenuity Pathway Analysis of the 32
diﬀerentially expressed target genes was DNA Replication,
Recombination, and Repair (Figure 6).
Expression patterns of miR-193b in human cancers,
unlike miR-10b, are largely variable. High expression of miR-
193b is frequently observed in head and neck squamous
cell carcinomas and is associated with a high risk of
metastaticdiseaseinuvealmelanoma[74,75].Conversely, in
other cancer types, overexpression of miR-193b has elicited
increased tumor suppression as well as sensitivity to speciﬁc
chemotherapeutics [57, 76, 77]. Moreover, conﬂicting results
have also been observed within a given cancer type. In
malignant cutaneous melanoma, overexpression of miR-
193b predicts disease outcome and is associated with poor
survival, while induced overexpression in cell lines repressed
proliferation through the downregulation of Cyclin D1 [78,
79]. Subsequent gene expression analysis of target mRNAs
of miR-193b revealed 10 genes that were underexpressed
in cell lines highly resistant to AZ628and 37 genes that
were underexpressed in cell lines highly resistant to MK-
0457. One of the target genes that was also diﬀerentially
expressed was IKAROS family zinc ﬁnger 1 (IKZF1). This
transcription regulating gene functions through associations
with complexes that are both histone deacetylase (HDAC)-
dependent and HDAC-independent [80]. Previous studies
have shown that nonhigh-risk ALL9 patients with IKZF1
deletions show a 12-fold higher rate of relapse compared
to patients without IKZF1 deletions and IKZF1 deletion
has also been implicated in tyrosine kinase inhibitor (TKI)
resistance and disease progression in patients with chronic
phase- (CP-) chronic myeloid leukemia (CML) [81, 82].
Overexpression of an Isoform of IKZF1 lacking a DNA
bindingdomain,IK6,inacutelymphoblasticleukemia(ALL)
patients with the Philadelphia chromosome has also been
associated with TKI resistance [83]. Interestingly, MK-0457
is a small molecule inhibitor chemotherapy drug that targetsJournal of Biomedicine and Biotechnology 11
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Figure 6: Overrepresented cellular and molecular functions that
are common to all four sets of diﬀerentially expressed target genes.
A “Core Analysis Comparison” was performed using Ingenuity
PathwayAnalysisandwithintheBiologicalFunctions,onlyfunctions
within Molecular and Cellular Functions were assessed. In total,
eight of these functions were signiﬁcant in all four sets. The orange
threshold line corresponds to a P-value of .05.
aurora kinase. Underexpression of IKZF1 as a result of miR-
193b targeted degradation may increase resistance to MK-
0457 in a similar mechanism to TKI resistance.
Similar to miR-193b, evidence supporting the role of
miR-328 in cancer is also unclear. In lung adenocarcinoma,
miR-328 has been shown to be overexpressed in tumor tissue
relative to matched nonmalignant tissue regardless of EGFR
or KRAS mutation status [28]. However, in other cancer
types, miR-328 underexpression, for example, enables drug
resistancethroughtheupregulation of ABCG2and correlates
with cancer progression [84–86]. Our analyses revealed miR-
328 to be gained and overexpressed in lung cancer cell
lines resistant to Geldanamycin, an antibody against HSP90.
Target and gene expression analysis of miR-328 identiﬁed
31 genes underexpressed in cell lines highly resistant to
Geldanamycin, with one of the targets being the Vitamin
Dr e c e p t o r(VDR). VDR and its downstream components,
have been previously shown to have antiproliferative eﬀects
in a wide variety of cancer types. The anticancer eﬀects
of VDR signaling are mostly mediated through its active
metabolite, 1,25-dihydroxyvitamin D (calcitriol), which has
beenshowntoexhibitanti-inﬂammatoryeﬀectsaswellasthe
suppression of tumor angiogenesis, invasion, and metastasis
[87, 88]. Expression of VDR has also been shown to be
associatedwithincreasedsurvivalinbreast,colorectalcancer,
and cholangiocarcinoma. It has been recently shown that
nuclear VDR status may be a prognostic marker of improved
survival in patients with NSCLC [88]. Another intriguing
ﬁnding for miR-328-associated mRNAs is the implication of
both H(+)-monocarboxylate cotransporter (MCT) proteins
1 and 4 (SLC16A1/MCT1 and SLC16A3/MCT4). MCT1 and
4areinvolved in lactateuptakeandpH balance.Inhibition of
MCT1intumorscanshiftaerobiccancercellsfromoxidative
phosphorylation(lactatemetabolism)toglycolysis(glucose),
resulting in the death of hypoxic tumor cells due to glucose
deprivation [89].
Relatively little has been reported with regard to the
role of miR-628. A recent study revealed that miR-628
was expressed in neuroblastomas with favorable prognosis,
while those with unfavorable prognosis were devoid of
expression, suggesting a tumor suppressive role in this type
of cancer [90]. From our analyses, we identiﬁed miR-628
to be gained and overexpressed in resistant lung cancer cell
lines treated with agent PF-2341066, a MET and ALK kinase
inhibitor which has recently shown tremendous eﬃcacy in
a subset of lung cancer patients [7]. While the direction
of expression contradicts the ﬁndings in neuroblastoma,
miRNA tissue speciﬁcity may play a role in diﬀerential
expression patterns. Regardless, further analysis of miR-628
is required to better elucidate its role in human cancers.
Target and gene expression analysis of miR-628 revealed 22
geneswhichwereunderexpressedincelllineshighlyresistant
to PF-2341066, with one of these diﬀerentially expressed
being caspase 3 (CASP3). CASP3 is a gene involved in the
caspase apoptosis cascade by activating caspases 6, 7, and 9
through cleavage [91]. Moreover, it is also used as a general
indicator of cell death and apoptosis. Notably, PF-2341066,
which functions as a TKI inhibitor, was found to induce the
caspase cell death cascade in vitro through increased levels
of CASP3 [92]. Thus, CASP3 downregulation, as a result of
miR-628 targeting, may play a signiﬁcant role in resistance to
PF-2341066.12 Journal of Biomedicine and Biotechnology
While all involved in response to diﬀerent drugs, the
targets of these miRNAs share certain biological functions.
Figure 6 illustrates the functions in which the targets of all
four miRNAs participate at a statistically signiﬁcant level.
Broadly,ifrolessuchascellularmaintenanceandDNArepair
were compromised, such cell populations could develop
tolerance to the accumulation of mutations, some of which
could dictate resistance. Participation in small molecule
biochemistry has implications in the alteration of how these
administered drugs are processed. Cellular organization and
cell-to-cell signaling, if altered, could confer a more invasive
phenotype, contributing to drug resistance.
5. Conclusions
In conclusion, we have demonstrated our method of inte-
grative analysis of multiple dimensions of data including
genome-wide miRNA copy number, miRNA expression,
mRNA expression, and drug sensitivity data, all available
in the public domain, can be a powerful tool to identify
miRNAs and genes involved in drug sensitivity. Through
these initial analyses, we have identiﬁed miRNAs that may
have a role in conferring chemoresistance to a number of
drugs. Further in vitro and in vivo analyses of the miRNAs
and their respective mRNA targets will be necessary to
conﬁrm the ﬁndings from this study. In addition, given
that nearly half of the miRNAs that were diﬀerentially
altered were not even represented on the miRNA platform
analyzed, evaluation of these miRNAs may prove fruitful
when new data becomes available. It should also be noted
that miRNA target prediction approaches and algorithms
are constantly evolving and increasing number of miRNA-
mRNA interactions being experimentally validated, poten-
tially revealing important target genes that are not currently
implicated. Finally, since the MGH/Sanger collaboration
aims to generate drug response proﬁles for a large number
of chemotherapeutics in over 1000 cancer cell lines, as
more data becomes available, our approach could identify
candidate miRNAs that are associated with multiple drugs
which have similar mechanisms of action. Moreover, our
strategy could also be repeated in a more speciﬁc and
clinically relevant manner, which could ultimately lead to
the identiﬁcation of prognostic biomarkers and therapeutic
indicators for better disease management and patient out-
come.
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